MedTrace Logo

Bariatric Embolization Trial for the Obese Nonsurgical

NCT03601273 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2018-07-26

No results posted yet for this study

Summary

The purpose of this study is to assess the safety profile of bariatric embolizations and confirm published reports of sustained post-procedural weight loss, and pathologically assess post-procedural metabolic effects.

Conditions

Interventions

PROCEDURE

Left gastric artery embolization

450-micron Embozene microparticles will be used intraarterially to occlude the left gastric artery and its branches. 30-day post-embolization endoscopic biopsy

Sponsors & Collaborators

  • Calgary Adult Bariatric Surgery Clinic

    collaborator OTHER

  • Peter Lougheed Center, Mayfair Diagnostics

    collaborator UNKNOWN

  • University of Calgary

    lead OTHER

Principal Investigators

  • Darshan Bakshi, MD · University of Calgary

  • Oliver Halliwell, MD · University of Calgary

  • Emeka Nzekwu, MD · University of Calgary

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-30
Primary Completion
2023-09-30
Completion
2023-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03601273 on ClinicalTrials.gov